PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for June 19, 2009 Subscribe to this News Feed    
 

IMULAN and ONCURA Establish New Cancer Program

New Cancer Program is Established in Comparative Oncology between IMULAN BioTherapeutics and Oncura Partners.

St. Joseph, MO (PRWEB) June 19, 2009 -- Imulan BioTherapeutics, LLC (IMULAN) and Oncura Partners announced formation of a personalized cancer program aimed at creating a patient specific approach to tumors. IMULAN's is using their apSTAR laser technology, for Autologous Patient Specific Tumor Antigen Response, to create a network of apSTAR centers. apSTAR works by stimulating a patient specific response against tumor cells, thereby creating tumor immunity and improving the rate of primary and metastatic regression. IMULAN recently licensed the global veterinary rights to apSTAR from ImmunoPhotonics, Inc, leading to the creation of IMULAN's new division, Veterinary Cancer Therapeutics (www.VetCancer.com).

Dr. Craig Woods, CEO of Imulan and Veterinary Cancer Therapeutics, stated, "We are delighted to work with Oncura Partners on this exciting new technology. Their pre-established oncology network combined with a progressive, forward looking approach to oncology will facilitate our ability to design new patient specific treatment protocols for veterinary cancer patients. Oncura Partners shares the same vision as IMULAN, which is to improve the treatment success of veterinary cancer patients."

Dr. Brian Huber, President of Oncura Partners, stated, "We are excited about apStAR's potential to truly make a difference in the lives of pets battling cancer. This unique approach to fighting cancer is where all the scientific research has been focused, using the patients immune system to fight the primary and metastatic cancer cells. We are privileged to partner with such a forward thinking company as Imulan BioTherapeutics."

About Oncura Partners: Oncura Partners is a company dedicated to helping veterinary practitioners manage oncology cases, as well as other chronic health conditions in pets. Oncura's unique partnership with the practitioner, specialist, pharmacies, in combination with a proprietary online medical record system, creates an efficient way for hospitals to improve overall medical management and patient compliance. Oncura focuses on raising the bar for all case management processes and help busy doctors accomplish this in their day to day practice setting. Oncura offers complete case management services at www.oncurapartners.com.

About Imulan: Imulan develops unique, precision immune regulating compounds for veterinary medicine. IMULAN is located in St. Joseph, MO and has diversified into biologics, vaccines, nutritionals, and medical devices to accommodate a growing demand for improved ways of treating disease. In addition, IMULAN has a growing laboratory service focused on immunology and tumor biology. For more information, visit www.IMULAN.com or www.VetCancer.com .

Contact Information:
Craig Woods DVM, MS, MBA
www.imulan.com

# # #

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/VGhpci1JbnNlLUNyYXMtRmFsdS1JbnNlLUNvdXAtWmVybw==

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareThis
CONTACT INFORMATION
Craig Woods
IMULAN BioTherapeutics, LLC
928.713.2334
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Close Move